INS and Hypoglycemia: The rate of patients that achieved an HbA1c <7.0% without developing clinically significant or severe hypoglycemia events at week 52 were significantly lower in patients receiving insulin icodec rather than the control (7.2% vs. 11.6%; estimated odds ratio = 0.59; 95%CI: 0.37 to 0.95) [40].